SELAGINE Inc. is a biotechnology company focused on developing novel therapeutics to help patients suffering from a variety of debilitating ocular diseases.
The word ‘Selagine’ is derived from Selaginella bryopteris - the botanical name for Sanjeevani Booti plant. Sanjeevani translates as "one that infuses life. According to Hinduism, Sanjeevani is a magical herb which has the power to cure serious medical problems. It was believed that medicines prepared from this herb could revive situations where death is almost certain.
SELAGINE Inc was launched at the University of Illinois at Chicago (UIC). UIC serves as a home life science firms at various stages of development within a vibrant entrepreneurial ecosystem that leverages University assets and connects Innovation, Infrastructure, Networks, Talent and Capital within and beyond the university.
Sandeep Jain, MD
Professor of Ophthalmology
Director, Dry Eye and oGVHD Clinic
Department of Ophthalmology
University of Illinois at Chicago
Dr. Sandeep Jain is a clinician-scientist and a Professor of Ophthalmology at the UIC Department of Ophthalmology. He is the Director of the UIC Dry Eye and ocular Graft-Vs-Host Disease clinic. He also directs the Cornea Translational Biology Laboratory in the Department. His research work is funded by the National Eye Institute/NIH and has led to numerous publications in professional journals as well as development of drugs for treating ocular GVHD that are in phase I/II clinical trials. He has received numerous awards and recognition, including UIC’s Inventor of the Year Award for his ocular GVHD drug discoveries, UIC’s Departmental Faculty of the Year Award and Clinician-Scientist Award from Research to Prevent Blindness. He has been named one of America’s Best Doctors® since 2007 and has received the American Academy of Ophthalmology’s Achievement Award.
After receiving his medical degree, Dr. Jain joined the Wilmer Ophthalmological Institute at The Johns Hopkins University as a pre-residency fellow and completed his residency training in Ophthalmology at the Harkness Eye Institute at Columbia University, New York, followed by subspecialty fellowship in Corneal Diseases at the Massachusetts Eye & Ear Infirmary/Harvard Medical School. Dr. Jain is the founding program director of the NEI/NIH funded Chronic GVHD Meeting in Chicago which focused on the intersection between the areas of chronic GVHD and dry eye/ocular surface disease. He is also the founder of UIC’s “goGVHD Fund” which seeks to provide novel treatments to all patients with ocular GVHD who need them, irrespective of their ability to pay and to lead the next generation of innovation to cure this disease.